Pesquisar um ensaio clínico
Outras opções de pesquisa
34 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ESPANHA
Madrid
MADRID
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
CABOPRE: Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A phase I-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
PAC203: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and Nivolumab in patients with select locally advanced or metastatic solid tumor malignancies - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
PASSPORT: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy (Phase II) - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
CheckMate 651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
TRITON: The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypetension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
OPTICS: An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing s Syndrome (Phase III) - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing s Syndrome (Phase III) - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
HIMALAYA: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (Phase II) - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
CAPTIVATE: Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Phase 4, open-label, randomized study of two inotuzumab ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno-occlusive disease - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
STAND: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea / Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
STEADFAST: A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients >= 16 years with chronic kidney disease due to sickle cell nephropathy - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap [...] - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
ESPANHA
Madrid
MADRID
SALTO: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged 2 to 18 years with Pulmonary Arterial Hypertension (Phase III) - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
LUMINA-1: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiva - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
ADVANCE: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP) - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Group 3 Pulmonary Hypertension - ES (completed)
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
SKYSCRAPER-07: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
ADVANCE+: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
ES-FISH: Effectiveness and Safety on Cardiac Frecuency Control With Ivabradine on the Cardiogenic Shock - ES
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID
Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive measures of progression in Huntington's disease patients
Hospital Universitario Ramón y Cajal
ESPANHA
Madrid
MADRID